Vancouver biotech company AbCellera is developing antibodies to treat COVID-19. In the six-minute video below from The Tyee, Ralph Pantophlet is interviewed alongside Véronique Lecault, COO of AbCellera. They explain what antibody treatment is and endeavors to apply it to COVID-19. The video also explains how advances in technology are helping to find and isolate the right antibodies.

 

Yiqiu, one of our talented undergrad research interns and a 3rd year student in the Department of Molecular Biology and Biochemistry, talks to SFU-SURJ (Science Undergraduate Research Journal) about the research that she has contributed to in the lab over the last several months.

[article]

Congratulations to Edarlin Bigornia, most recent undergraduate member of the Pantophlet Lab, who convocated this past week!

 

Official announcement of funding through the Canada Foundation for Innovation’s John R. Evans Leaders Fund (JELF). The Hon. Kirsty Duncan, Minister of Science and Sport, made the announcement today while visiting SFU’s Burnaby Campus. Dr. Ralph Pantophlet is one of three SFU lead researchers to receive JELF funding. The Pantophlet lab will acquire a new-generation flow cytometry system, enabling high-resolution analyses of immune responses and precise recovery of immune cells, thus stimulating new vaccine and cure strategies.
[Government of Canada announcement] [PDF]
[Simon Fraser News announcement] [PDF]

SFU has entered into a license agreement for the Trianni Mouse™, a best-in-class human monoclonal antibody discovery platform. The platform incorporates a complete human antibody repertoire and will support HIV, influenza and other vaccine research and development efforts in the Pantophlet Lab.

[article]